3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 1
1
Status
Terminated
2
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Head & Neck
6
Genitourinary
5
Other hematologic neoplasm
4
Lymphoid
4
Dermatologic
4
CNS
4
Thoracic
3
Gastrointestinal
3
Sarcoma
2
Gynecologic
2
Plasma cell
1
Breast
1
Conditions
Melanoma
273
Carcinoma, Non-Small-Cell Lung
49
Carcinoma, Renal Cell
37
Uveal Melanoma
23
Skin Neoplasms
23
Neoplasm Metastasis
23
Colorectal Neoplasms
22
Carcinoma, Transitional Cell
20
Carcinoma, Merkel Cell
20
Squamous Cell Carcinoma of Head and Neck
19
Neoplasms
18
Lung Neoplasms
17
Carcinoma, Hepatocellular
16
Brain Neoplasms
16
Triple Negative Breast Neoplasms
14
Uterine Cervical Neoplasms
13
Ovarian Neoplasms
13
Stomach Neoplasms
12
Urinary Bladder Neoplasms
10
Small Cell Lung Carcinoma
10
Head and Neck Neoplasms
9
Lymphoma
8
Carcinoma, Basal Cell
8
Pancreatic Neoplasms
7
Esophageal Neoplasms
7
Breast Neoplasms
7
Kidney Neoplasms
6
Sarcoma
5
Prostatic Neoplasms
5
Hodgkin Disease
5
Interventions
Peripheral Blood Stem Cell Transplantation
23
fludarabine phosphate
20
Cyclophosphamide
18
Mycophenolic Acid
16
Whole-Body Irradiation
15
Cyclosporine
15
Busulfan
12
Tacrolimus
11
Methotrexate
10
Antilymphocyte Serum
9
Radiotherapy
8
Melphalan
8
Etoposide
8
pembrolizumab
7
Methylprednisolone
6
Filgrastim
6
Sirolimus
4
Prednisone
4
Nivolumab
4
sargramostim
3
Vincristine
3
Transplantation
3
Therapeutics
3
Polymerase Chain Reaction
3
Cord Blood Stem Cell Transplantation
3
Amplified Fragment Length Polymorphism Analysis
3
mogamulizumab
2
merphos
2
bempegaldesleukin
2
Voriconazole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Recurrence
×
Nivolumab
×
Dermatologic
×
Clear all
NCT03686124
2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2
Recruiting
375 enrolled
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts
NCT00441337
2015-02-20
MDX1106-01
Bristol-Myers Squibb
Phase 1
Completed
39 enrolled
28 charts